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Prenatal Diagnosis by Targeted Haplotyping
Carlo Vermeulen,1 Geert Geeven,1 Elzo de Wit,1,12 Marjon J.A.M. Verstegen,1 Rumo P.M. Jansen,2
Melissa van Kranenburg,1 Ewart de Bruijn,2 Sara L. Pulit,2 Evelien Kruisselbrink,3 Zahra Shahsavari,4
Davood Omrani,5 Fatemeh Zeinali,6 Hossein Najmabadi,6 Theodora Katsila,7 Christina Vrettou,8
George P. Patrinos,7 Joanne Traeger-Synodinos,8 Erik Splinter,9 Jeffrey M. Beekman,3
Sima Kheradmand Kia,10 Gerard J. te Meerman,11 Hans Kristian Ploos van Amstel,2
and Wouter de Laat1,*
During pregnancy, cell-free DNA (cfDNA) in maternal blood encompasses a small percentage of cell-free fetal DNA (cffDNA), an easily
accessible source for determination of fetal disease status in risk families through non-invasive procedures. In case of monogenic heri-
table disease, backgroundmaternal cfDNA prohibits direct observation of thematernally inherited allele. Non-invasive prenatal diagnos-
tics (NIPD) of monogenic diseases therefore relies on parental haplotyping and statistical assessment of inherited alleles from cffDNA,
techniques currently unavailable for routine clinical practice. Here, we present monogenic NIPD (MG-NIPD), which requires a blood
sample from both parents, for targeted locus amplification (TLA)-based phasing of heterozygous variants selectively at a gene of interest.
Capture probes-based targeted sequencing of cfDNA from the pregnant mother and a tailored statistical analysis enables predicting fetal
gene inheritance. MG-NIPD was validated for 18 pregnancies, focusing on CFTR, CYP21A2, and HBB. In all cases we could predict the
inherited alleles with >98% confidence, even at relatively early stages (8 weeks) of pregnancy. This prediction and the accuracy of
parental haplotyping was confirmed by sequencing of fetal material obtained by parallel invasive procedures. MG-NIPD is a robust
method that requires standard instrumentation and can be implemented in any clinic to provide families carrying a severe monogenic
disease with a prenatal diagnostic test based on a simple blood draw.Introduction
Fragmented DNA expelled by apoptotic cells into the
blood plasma is an easily accessible source of biomarkers
originating from non-self cells by virtue of their distinct
genetic composition. These can be cancer cells carrying a
rearranged or mutated genome1,2 or cells of fetal origin.3
During pregnancy, a fraction of the maternal cell-free
DNA (cfDNA) consists of cell-free fetal DNA.4,5 This fetal
fraction (FF) in maternal cfDNA has enabled non-invasive
prenatal testing (NIPT) for aneuploidy to enter routine
clinical practice.6,7 NIPT to detect trisomies is carried out
through deep sequencing of maternal cfDNA, followed
by a search for significant overrepresentation of fragments
originating from a particular chromosome. NIPT circum-
vents the (perceived) burden of invasive procedures
such as chorionic villus sampling (CVS) and amniocen-
tesis, each associated with a small increased risk of miscar-
riage.8–10 A similar non-invasive prenatal diagnosis (NIPD)
method based on a simple blood draw during pregnancy
would be highly beneficial for parents at risk of conceiving1Hubrecht Institute-KNAW and University Medical Center Utrecht, Uppsalala
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would require an accurate assessment of fetal inheritance
of point mutations or small indels, but the relatively
low contribution of cffDNA to the pool of maternal
cfDNA (typically 2%–20%) complicates robust and unam-
biguous identification of both transmitted alleles through
NIPD.11,12
Determining the paternally inherited allele in maternal
cfDNA is straightforward when the father contributes
sequence variants not carried by the mother, as is often the
case. Detection of these variants implicitly uncovers the
paternally inherited allele.11,13,14 NIPD for paternally in-
herited risk alleles is already applied in clinical prac-
tice.11,15,16 Determining which maternal allele is inherited
bythe fetus is farmore challenging,however, since this allele
is genetically identical to one of thematernal alleles present
in the cfDNA. Identification of the maternally inherited
allele therefore requires accurate assessment of which of
the two alleles is overrepresented in the cfDNA due to both
fetal andmaternal contributionversus the allele contributed
only maternally. Directly linking the heterozygous SNPs inan 8, 3584 CT Utrecht, the Netherlands; 2Department of Medical Genetics,
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Figure 1. Strategy for Monogenic Non-Invasive Prenatal
Diagnosis
(A) Summary of the MG-NIPD approach. Blood is isolated from
both parents and cells are used to TLA haplotype the disease locus.
Cell-free DNA is isolated from maternal plasma during pregnancy
and sequenced to analyze cell-free fetal DNA. Parental locus-
specific haplotypes are used to discern which combination of
parental alleles is overrepresented in cell-free DNA and therefore
inherited by the fetus.
(B) Targeted haplotyping by TLA. Crosslinking (blue ovals), diges-
tion, and proximity ligation primarily yields intra-chromosomal
ligation products. Ligation products containing a (viewpoint)
SNP of interest (yellow and green triangles) can be selectively
amplified by inverse PCR and sequenced. Variants ending up in
the same ligation product (indicated by blue and red triangles,
respectively) are assigned to the same allele (phasing).and around the gene of interest to either the mutated or
wild-type allele of each parent (called phasing or haplotyp-
ing) is thus critical, as the resulting haplotype will yield a
high number of informative variants that can be used as a
proxy for either the disease or the healthy allele in cfDNA.
Identification of many such allele-distinguishing variants,
coupled with higher fetal fraction, allows for more robust
assessment of the inherited allele in the fetus. Since it is aThe Americanpriori unknown how small the fetal fraction will be, a high
number of heterozygous variants must be phased to either
the disease-linked or wild-type allele. The sequencing and
counting of these variants in cfDNA fragments from the
pregnantmother then helps determinewhich of the two al-
leles is overrepresented in cfDNA and is therefore themater-
nally inherited allele.17–20
For NIPD of monogenic diseases to be routinely appli-
cable in clinical practice, it must be accurate, broadly
employable to different monogenic diseases, efficient (in
time and resources) in returning results, and cost effective.
Strategies that rely on whole-genome haplotyping of
the two parents21–23 are currently too expensive and too
analysis intensive to be broadly applicable in the clinic.
Furthermore, diagnosis should preferably be feasible
without requiring the presence of a proband,15,16,18,24,25
particularly in a society in which people increasingly have
knowledge about their disease carrier status and therefore
would want to apply NIPD to their first child. Thus,
methods for efficient targeted haplotyping of both parents,
combined with targeted deep sequencing of cfDNA, are
needed (Figure 1A).
To cost effectively acquire parental haplotypes for NIPD,
we implemented the recently developed targeted locus
amplification (TLA)26 method to perform haplotyping
specifically around genes of interest. Compared to existing
targeted haplotyping strategies, such as long-range PCR
or digital (droplet) PCR,27–29 the TLA technology better
enables phasing of dispersed blocks of heterozygous SNPs,
even when they are interrupted by long stretches of homo-
zygosity, and is capable of phasing many SNPs per set of
primers.26 cfDNA is then isolated frommaternal plasmadur-
ing pregnancy, enriched for fragments originating from the
locus of interest, and sequenced. The haplotype data along
with the cfDNA sequence reads are used to determinewhich
haplotypes have been inherited by the fetus. As a proof-
of-principle for this approach, we focused on the cystic
fibrosis transmembrane regulator (CFTR [MIM 602421])
locus, as severe loss-of-function mutations in CFTR are
known to cause cystic fibrosis (CF [MIM 219700]),30 and
the cytochrome P450 family 21 subfamily A polypeptide 2
(CYP21A2 [MIM: 613815]) locus, which can contain muta-
tions causal for congenital adrenal hyperplasia (CAH
[MIM: 201910]).31 To investigate the flexibility of our
method in additional monogenic diseases, we applied this
strategy to ten b-thalassemia (MIM: 613785)-risk families.Material and Methods
Organoid and Cell Cultures
Leftover rectal biopsies isolated for diagnostic care were used to
generate organoid cultures, and informed consent was given for
organoid biobanking and the purpose of the study. Organoids
were cultured as described.32 IB3-1 cells were grown as adherent cul-
tures in LHC-8 medium (GIBCO) supplemented with 10% fetal
bovine serum and 1% P/S and negatively tested for the presence of
mycoplasma.Journal of Human Genetics 101, 326–339, September 7, 2017 327
Sample Preparation
Leftover blood drawswere used from anonymous couples forCFTR
and CYP21A2 MG-NIPD. The women were at approximately
20 weeks of gestation when fetal anomalies where detected by
ultrasound examination. Amniocentesis was performed for diag-
nostic testing of copy-number variations. High-molecular-weight
DNA was isolated from whole blood according to established
procedures using a Chemagic Magnetic Separation Module 1
(PerkinElmer). Blood draws were used from b-thalassemia-risk
families before CVS procedure. Pregnancies were at approximately
11 weeks gestation (lowest: 7 weeks and 5 days, highest: 11 weeks
and 3 days). The use of leftover material for development of new
and improved techniques was in accordance with the policy of
the UMC Utrecht. In non-Dutch enrollment centers, these studies
were approved by the appropriate national ethics authorities.
Additional genomic DNA for SNP genotyping was isolated dur-
ing TLA template preparation. Plasma was isolated from blood
cells by centrifugation of whole blood at 1,600 3 g and superna-
tant was subsequently centrifuged at 16,000 3 g for 10 min and
stored at 80C. cfDNA was then isolated from the blood plasma
using a QIAamp DNA BloodMini Kit (QIAGEN). DNAwas isolated
from amniotic cells and CVS samples based on phenol extraction
according to established procedures.
Viewpoint Genotyping
To identify heterozygous SNPs useable as anchors (viewpoints) to
be phased with surrounding variants by TLA, we performed PCR
reactions on genomic DNA. FW and SEQ primers (Tables S1 and
S2) were combined in PCR reaction using Q5 high fidelity poly-
merase (New England Biolabs). PCR reactions were pooled per
individual and purified using QIAGEN PCR purification columns
(QIAGEN). Sanger sequencing was subsequently performed by
Macrogen Europe using the SEQ primer.
Targeted Locus Amplification
TLA template was prepared from blood samples as described by De
Vree et al.26 In cases where both cells (for TLA) and cfDNA were
isolated from the same blood sample, 5 mL whole blood was
centrifuged at 1,600 3 g for 10 min, and plasma was then used
for cfDNA isolation while the cell pellet was resuspended in a
10% fetal bovine serum solution in PBS and treated identical to
whole blood for the purpose of template preparation. To create sin-
gle-cell suspension from organoid cultures, they were treated with
trypsin for 5 min at 37C and disintegrated by pipetting. IB3-1
cells were treated with trypsin until they detached from culture
plates and brought into single-cell suspension by pipetting. Sin-
gle-cell suspensions from organoids or IB3-1 cells were treated
identically to isolated white blood cells. PCR was performed as
described in De Vree et al.26 using the FW and RV primers
described in Tables S1 and S2, using 100 ng of template per reac-
tion. PCRs were pooled per person prior to tagmentation using
nextera XT kit and protocol (Illumina). Tagmented libraries were
pooled and sequenced using Illumina miseq, miniseq, or nextseq
sequencing platforms with paired-end 150 basepair reads.
Targeted cfDNA Enrichment
A custom Sureselect library was designed (Agilent) for SNPs with
>10% heterozygosity in the Dutch population as determined in
the Genome of the Netherlands Consortium,33 the probeset was
designed with 53 tiling. For all families, cfDNA pulldown was
conducted according to the Sureselect XT2 kit and protocol, with328 The American Journal of Human Genetics 101, 326–339, Septemomission of the fragmentation step, since cfDNA is already frag-
mented. Adaptor mixes were prepared by mixing three stock
adapters to maximize unique fragment recovery and diluted 1:20
prior to adaptor ligation, to compensate for the low input quanti-
ties. Up to five cfDNAs were pooled in equal amounts after index-
ing PCR for simultaneous probe hybridization. For the HBB region,
SNPs from the dbSNP 1.4.4 database with an average heterozygos-
ity of >10% were selected; probes were designed so that each SNP
was covered by six tiled probes, three containing the reference
allele, and three containing the alternative allele.
Haplotype Assembly
Raw TLA sequence data were mapped using the BWA SW algo-
rithm to the hg19 human reference genome (UCSC release
GRCh37). Heterozygous SNPs were called using a dedicated script,
selecting only SNPs with >15% of reads containing the minor
allele and aminimum coverage of 253. Sequence reads containing
multiple heterozygous SNP variants were then extracted and each
link was counted as described in De Vree et al.26 Subsequently, a
custom haplotyping script was used to construct haplotypes.
This script was designed to allow construction of haplotypes,
even in the presence of some ambiguous links, where SNPs are
found with links to both haplotypes. These links may arise due
to sequence errors, PCR artifacts, and perhaps an occasional rare
inter-chromosomal contact. Furthermore, the method used here
assumes all heterozygous SNPs are bi-allelic, and therefore when
one variant is attributed to one haplotype, the other variant can
automatically be assigned to the other haplotype (with similar po-
wer). In short, the highest covered heterozygous SNP is identified
and each variant is assigned to a different haplotype: they serve as
fixed starting variants for haplotype assembly (seeds). Subse-
quently, 25 iterations are performed to stepwise extend the haplo-
type size, each time adding the most strongly associated (mostly
strongly linked and least ambiguous) variants to one of two haplo-
types. During the first five iterations, only SNPs where both vari-
ants are linked to opposite haplotypes are accepted into the core
haplotype, with a strength threshold that decreases per iteration.
In the subsequent 15 iterations, only SNPs are accepted where
both alleles are found with links to opposite haplotypes without
a strength threshold and in the five final iterations SNPs are
accepted where both alleles are found with links but with only
one allele linking to a haplotype. Linkage of the other allele is
assumed in these cases. After the 25th iteration, a final step is
added to link poorly covered SNPs, where only one allele is found
with links. Here, only SNPs without ambiguous links are accepted
and mirrored links are not assumed (Figure S1). We note that al-
lowing ambiguous links increases the size of haplotypes but also
increases the chance of erroneous assignments. A small percentage
of falsely assigned neutral SNPs does not necessarily affect the
predictive power of MG-NIPD but needs to be strictly avoided
for disease mutations. Therefore we confirmed that all identified
disease mutations as well as the wild-type alleles were indeed
both linked unambiguously. Haplotypes shown as ‘‘spidergraphs’’
or clusters show all direct non-ambiguous links used to construct
haplotypes. For the analysis of inherited alleles, the two haplo-
types are merged and SNPs where only one variant is directly
linked but where a reliable (>253 coverage,>15%minor allele fre-
quency [MAF]) heterozygosity call was made are included. For the
F508del viewpoint, and the deletions and insertion found in some
b-thalassemia carriers, which are not single-nucleotide variants,
and therefore are not recognized by the regular pipeline, a modi-
fied script was designed to extract all sequence reads containingber 7, 2017
either the deletion or the wild-type allele. Discordant positions
were identified between the two split datasets and added as links
to the set of links identified by the regular pipeline.cfDNA Sequence Data Processing
cfDNA reads were mapped using BWA MEM to a custom SNP-
masked genome (hg19) where the reference sequence of all dbsnp
1.4.2 SNPs in the region of interest were masked to avoid a map-
ping bias. Duplicates were removed per index using samtools
rmdup. Since many cfDNA fragments are shorter than 300 bp,
and we used PE150 sequencing, we removed overlapping reads
using Genome Analysis Toolkit clip-overlap. Pools of the same
sample were merged using samtools after processing. Pileup data
were also generated using samtools, SNPs with coverage <20
were excluded. We note that, despite mapping to a masked
genome, we still identified a small (1%) bias toward reference
variants in the CFTR analyses. We note that implementing a
compensation step for this bias does not change the outcome of
any inheritance predictions.NIPD Analysis
We adapted our NIPD analysis from the RHDO analysis described
by Lo et al.19 Aside from generating haplotypes, a pileup is created
from TLA data, for all known dbsnp 1.4.2 SNPs in the region of
interest.
For class 1 SNPs, homozygous positions are identified from TLA
data with more than 303 coverage and <5% discrepant reads. Of
note, this selection may still include heterozygous SNPs in rare
cases. From this pileup, class 1 SNPs are selected where opposing
alleles are present between parents. For the purpose of FF estima-
tion, we exclude all SNPs where >40% and >20% of sequence
reads are from the paternal allele for CFTR and HBB, respectively,
since these are most likely maternal non-homozygous SNPs. Class
2 SNPs are identified by comparing the paternal haplotypes with
the homozygous maternal SNPs. Observations discrepant to the
maternal variant are counted for positions where paternal haplo-
type 1 would be visible if inherited and for positions where
paternal haplotype 2 would be visible if inherited. This typically
shows one highly overrepresented allele (Figure 3), both relatively
and quantitatively: the paternal haplotype with the highest num-
ber of observations is then selected as the inherited paternal
haplotype. The inherited paternal haplotype is then extended
with all reliably determined homozygous paternal SNPs. Maternal
inheritance is based on estimates of the fraction of alleles for the
two different types of class 3 maternal SNPs in a given family. We
compensate these estimates for overdispersion that is common in
high throughput sequence count data, and confidence intervals
for fractions of class 3 SNPs are adjusted accordingly. Overdisper-
sion was estimated by comparing the variance of all non-overrep-
resented SNPs of all families with the theoretical variance of
independent observations. We use the corrected estimates of
the standard deviation and derived z-scores from the estimated
fractions in order to compute clinically relevant posterior risks
(Table 1 and Technical Appendix).Overdispersion
Sequence reads cannot be assumed to be completely independent,
due to their PCR-based nature and possibly due to incomplete
duplicate removal, resulting in overdispersion. The level of over-
dispersion in the entire dataset was calculated by comparing the
variance of the allele fractions at individual SNPs for which over-The Americanrepresentation was not expected to the theoretically expected
variance in the case of independent observations. The per-family
overdispersion was calculated using the variance of a Z trans-
formed proportion, computed for each SNP. When the observed
variance of Z is larger than 1.0, this implies overdispersion.We cor-
rect for overdispersion in our estimate of the variance of the allele
fractions which causes the confidence interval for the proportion
of alleles to be wider. The Z score transformed proportion for
equally represented alleles is computed over all similarly distrib-
uted SNPs using the formula





where Fa is the proportion of alleles A and Na and Nb are the
numbers of observed alleles A and B. Let bsF a denote the sample
standard deviation estimate of Fa (assuming independent
reads) and let bsZ be the estimate of the SD of Z. Then the overdis-
persion-corrected SD of Fa becomes dsF a ¼ bsF a  bsZ. We use the
overdispersion-corrected SDs in our calculation of the posterior
risks.Posterior Risk Calculation
The posterior risks were calculated using a normal approximation
for the distribution of the proportions. The a posteriori risk of trans-
mission of amaternal allele to the child uses both type 3A and type
3B SNP data, assuming independence between reads of the two
types. If a read contains information on both types of alleles, there
is dependency between the two sets. This is a second-order effect
that is neglected in the computation because it is rare in practice.
Since some of the families in this study do not have a risk allele,
the risk of inheritance is calculated for maternal haplotype 2.
The likelihoods of the observed data from both SNP types can be
computed by multiplication of the appropriate probability den-
sities conditional on the maternal inheritance and for a given
the fetal fraction as follows: 4ðx j m; sÞ denotes the probability den-
sity function of a normally distributed random variable X with
mean m and standard deviation s. FA denotes the observed fraction
of alleles linked to the maternal risk (or haplotype 2) allele for A
SNPs and FB the same fraction for B SNPs. The overdispersion-cor-
rected standard deviations of these fractions we denote by sA and
sB. The likelihood for type A SNPs, when the maternal risk allele is
transmitted, is given by A ¼ 4ðFA j0:5; sAÞ and the likelihood for
type B SNPs is given by B ¼ 4ðFB j0:5þ ðFF=2Þ; sBÞ: When the
mother transmitted the unaffected allele, the likelihood for type A
SNPs is C ¼ 4ðFA j0:5 ðFF=2Þ;sAÞ and the likelihood of type B
SNPs is then D ¼ 4ðFB j0:5; sBÞ. These four separate likelihoods
can be understood as follows: A measures whether haplotype 2
(or the disease haplotype) is being equally represented in 3A
SNPs, and B whether haplotype 2 is being overrepresented at the
same time in 3B SNPs. C measures whether maternal haplotype
2 is being underrepresented in 3A SNPs and D whether haplotype
2 is equally represented in 3B SNPs. Since A and B are indepen-
dently confirming the same hypothesis (mHap2/AF inherited),
and C and D are independently confirming the alternate hy-
pothesis (mHap1/WT inherited), we compare A*B and C*D to
determine the likelihood of the data under each hypothesis. The
posterior risk for a given fetal fraction is thus given by the ratio
(AxB) / (AxBþCxD). The fetal fraction is used as weight and inte-
grated out as nuisance parameter, using a density based on the esti-
mated fetal fraction and its overdispersion-corrected variance. For
more details and a worked out numerical example, see the Tech-
nical Appendix.Journal of Human Genetics 101, 326–339, September 7, 2017 329
Table 1. Overview of MG-NIPD Results
Fam FF (%) Class 1 Class 2 Class 3 Tot. Correct Unk Accuracy (%) Reads mhap phap Post Risk (%)
CFTR 1 26.0 9 190 187 386 378 6 99.4 23,079 2 1 >99.9
CFTR 2 6.0 10 158 229 397 381 14 99.5 19,530 2 2 >99.9
CFTR 3 19 22 62 197 281 275 5 99.6 32,188 1 1 <0.01
CFTR 4 6.1 109 142 163 414 399 13 99.5 28,637 1 1 0.3
CFTR 5 7.6 21 242 86 349 328 15 98.2 9,170 2 1 99.7
CFTR 6 9.4 55 94 138 287 271 12 98.5 16,333 1 1 <0.01
CFTR 7 32.8 9 100 107 216 196 16 98.0 22,823 2 1 >99.9
CFTR 8 17.1 39 105 147 291 267 23 99.6 16,555 2 2 >99.9
CFTR 9 19.7 63 66 197 326 305 17 98.7 35,077 1 2 <0.01
CYP 1 26.0 (CFTR) 0 15 183 198 194 1 98.4 19,525 2 1 >99.9
CYP 3 20 19 47 214 280 259 12 96.6 29,423 2 1 >99.9
HBB 1 7.8 11 86 258 355 – – – 20,086 AF AF 99.6
HBB 2 5.8 14 179 300 493 – – – 25,770 AF AF 99.9
HBB 4 9.6 119 304 485 908 762 139 99.0 19,463 WT WT <0.01
HBB 5 13.6 1 83 596 680 572 99 98.4 38,099 AF WT >99.9
HBB 6 10.5 0 19 515 534 462 55 96.4 44,935 AF WT 99.8
HBB 7 8.0 6 287 616 909 769 137 99.6 48,448 AF WT >99.9
HBB 8 7.2 0 206 241 447 432 9 98.6 21,609 AF AF 99.3
HBB 9 7.1 142 306 257 705 419 278 98.1 12,460 AF AF >99.9
HBB 11 6.9 26 58 165 249 223 16 95.7 20,410 AF WT 98.1
The outcomes of the MG-NIPD procedure in families 1–9 testing for CFTR, CYP21A2 (in two families, denoted CYP 1 and CYP 3), and the nine included b-thal-
assemia risk families (HBB 1–11, excluding 3 and 10). Listed is the estimated fetal fraction (FF) based on class 1 and 2 SNPs, the number of SNPs identified within
each class, and the total number of SNPs for which a genotype was predicted. ‘‘Correct’’ indicates the number of predicted genotypes that were confirmed in the
amniocentesis or CVS sample, and ‘‘Unk’’ indicates SNP genotypes that could not be called in the amniocentesis or CVS sample (i.e., were unknown). ‘‘Accuracy’’
indicates the concordance between the genotypes established using TLA and genotypes confirmed through targeted sequencing. ‘‘Reads’’ indicates the raw num-
ber of informative sequence reads obtained (for maternal inheritance) from cfDNA in each family. ‘‘Mhap’’ and ‘‘Phap’’ indicate which maternal haplotype (mhap)
and paternal haplotype (phap) have been inherited. ‘‘Post risk’’ indicates the posterior risk for inheritance of maternal haplotype 2 (for CFTR and CYP21A2) or the
affected maternal haplotype (for HBB).Theoretical NIPD Requirements
The theoretical required number of reads to reliably detect an over-
representation of a maternal haplotype for a given FF was calcu-
lated based on the expected frequency of overrepresented
maternal alleles, while ignoring paternally derived reads.
Fraction inherited hap alleles ¼ Inherited hap allele frequency/
total read number
Inherited haplotype allele frequency ¼ ð1 FFÞ þ FF
Non inherited haplotype frequency ¼ 1 FF
Inherited haplotype fraction ¼ ð1 FFÞ þ FFð1 FFÞ þ FF þ ð1 FFÞ ¼ 1=ð2 FFÞ
The theoretical number of independent and informative reads
(N) required to detect a significant deviation from 50% is then
calculated:
0:5 1=ð2 FFÞ ¼ 3=ð2  OðNÞÞ
N ¼ 94  ð0:5 1=ð2 FFÞÞ^2330 The American Journal of Human Genetics 101, 326–339, SeptemThis equation was transformed into the formulas shown in
Figure S8.Graphics
Graphs were made using the R package ggPlot2 (v.1.0.1) and
Microsoft Excel. Spiderplots, bar graphs, boxplots, and class 3 dis-
tributions were made using R v.3.1.2. Heatmap displays of haplo-
types were made using the gplots (v.2.17.0) R package. Clustered
haplotype views were made using Cytoscape (v.3.2.1). Sequence
data and refseq gene panels were made using Integrated Genome
Viewer (v.2.3). Images were further formatted using Adobe illus-
trator CS6.Results
We first validated our ability to haplotype the CFTR locus
by phasing variants in and around the gene. Briefly, TLA
uses fixation, digestion, and ligation of DNA fragments
that are linearly and physically close together on the chro-
mosome in intact cells. Selective amplification and high
throughput sequencing of ligation products formed withber 7, 2017
Figure 2. TLA Haplotyping of the CFTR Region
(A) TLA haplotyping results obtained from organoids derived from a CF carrier (GenBank: NM_000492.3; c.[1652_1654del];[¼]). TLA
sequence coverage (plotted in gray, trimmed at 2503) spanned a 710 kb chromosomal interval around the CFTR gene. Informative
SNPs in this region inform phasing to construct the c.1652_1654del (top, in red) and unaffected (i.e., wild-type, bottom, in blue) hap-
lotypes. Locations of TLA viewpoints used for this experiment are indicated by black triangles with extended dashed lines. For each
allele, the number of independently phased SNPs is shown as well as its total number of phased SNPs (which is based on the merge
(legend continued on next page)
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a fragment of interest (called a ‘‘viewpoint’’) allows tar-
geted sequencing of a locus. Since intra-chromosomal
crosslinks and ligation events are highly favored over
inter-chromosomal events, pairs of SNPs found within
the same ligation product can be faithfully assigned to a
haplotype (Figure 1B).
We applied TLA to the IB3-1 CFTR compound heterozy-
gous cell line (GenBank: NM_000492.3; c.[1652_1654del];
[3978G>A])34 and organoid lines derived from two indi-
viduals affected by CF (GenBank: NM_000492.3;
c.[1652_1654del];[482G>A] and GenBank: NM_000492.3;
c.[1652_1654del];[3884G>A]) and an individual with CF
carriergenotype (GenBank:NM_000492.3; c.[1652_1654del];
[¼]).32 A series of TLA viewpoints spread across hundreds of
kilobases around CFTR were designed, each at a common
SNP and one at the most recurrent CF variant, the CFTR-
F508del trinucleotide deletion (GenBank: NM_000492.3;
c.[1652_1654del]).35 PCR and Sanger sequencing were
used to verify which of these viewpoint SNPs was heterozy-
gous in a given cell line, a prerequisite for efficient TLA
haplotyping, as such SNPs serve as the anchors to be phased
to surrounding SNPs by TLA (Table S1 and Figure S2). In all
instances, TLA successfully linked the pathogenic variants
to many neutral SNPs. Links between individual SNPs
spanned up to 600 kb. We identified and assigned 123–
374 heterozygous SNPs, spread over approximately 710
kb, to each haplotype (Figures 2A–2E and S3A–S3F). In
one of the organoid lines (GenBank: NM_000492.3;
c.[1652_1654del];[3884G>A]), an a priori unknown addi-
tional disease mutation (GenBank: NM_000492.3;
c.[1655T>C]) was detected (Figures 2D, S3F, and S3G).
TLA further identified common SNPs that were homozy-
gous in a given cell line, which, as explained below, are
essential to determine information from cfDNA. We
observed a very high similarity between the four F508del
haplotypes (Figure S3H) which suggests that the F508del
mutation arose in a common ancestor of these persons
and provides evidence for the accuracy of TLAhaplotyping.
Wenote that the sizes of the identifiedhaplotypes caneasily
be increased by the design and inclusion ofmore TLA view-
points at heterozygous SNPs; such a design was not applied
to these test samples. Based on this pilot data, we concluded
that our TLA-based strategy for CFTR haplotyping could
distinguish disease fromwild-typeCFTR alleles and allowed
for the phasing of SNPs over hundreds of kilobases of a
genomic region of interest.of the two collections of directly phased SNPs, i.e., when allele 1 is lin
type 2 and vice versa).
(B) Clustered representation of the constructed c.1652_1654del/WTc
color representing which of the two haplotypes it has been assigned
represents one or more ligation products found between two alleles,
yellow.
(C–E) Haplotypes generated for the compound heterozygous CF organ
(D) GenBank: NM_000492.3; c.[1652_1654del];[3884G>A] and th
[3978G>A].
(F) Schematic representation of the 36 CFTR haplotypes constructed
haplotypes were expanded to also include identified homozygous S
represent the alternative variant. White bars represent SNPs where v
332 The American Journal of Human Genetics 101, 326–339, SeptemSubsequently, leftover sample was obtained from nine
anonymous couples, where fetal anomalies were detected
by ultrasound examination and amniocentesis was per-
formed for diagnostic testing of copy number variations.
We used the leftover sample to validate our strategy for
non-invasive prenatal CFTR diagnostics. Despite there
being no pathogenic variants present in these families,
determining the combination of haplotypes transmitted
to the fetus follows an identical procedure to diagnosing
the transmission of a pathogenic variant. A TLA template
was prepared from white blood cells. For each individual,
the heterozygous SNPs providing informative TLA view-
points were determined based on PCR and Sanger
sequencing (Table S3). TLA haplotyping applied to the 36
CFTR alleles of the 18 individuals yielded haplotypes
composed of 134–339 SNPs spanning 507–710 kb (Figures
2G, 3A, S4, and S5).
Tomaximize cfDNA sequencing efficiency, we combined
the targeted CFTR haplotyping strategy in parents with a
targeted sequencing strategy36 that selectively analyzes
the informative CFTR sequences present in cfDNA. To
this end we designed a capture probe library for the specific
pulldown and enrichment of 874 SNPs (cut-off > 10%
heterozygosity in the human population of interest33) in
a 710 kb interval centered on CFTR. Barcoded adapters
for Illumina sequencing were fused to the purified frag-
ments with a multi-indexing strategy (Figure S6A) and
between 5 and 16 million DNA fragments were sequenced
from both ends. Fragments with identical start and end
position and identical barcodes were considered PCR du-
plicates and removed from the dataset. Roughly 10% of
all sequenced cfDNA fragments were mapped to the region
of interest after pulldown, resulting in median coverage
(unique informative reads) of 83- to 213-fold across the
selected SNPs of the CFTR locus (Figures 3B and S6B).
To determine the haplotypes inherited by the fetus, we
modified an existing method, called relative haplotype
dosage (RHDO) analysis,19,20 as follows. From parental
TLA data, we identified the SNPs at which both parents
were homozygous but each for a different allele (class 1
SNPs); at these genomic positions, the father contributes
unique variants for which the fetus must be heterozygous
(Figure 3C). Such SNPs, if available, allow us to estimate the
percentage of cfDNA that was contributed by the fetus, as
two times the observed paternally derived fraction. The
observed fetal fraction differed widely across the nineked to haplotype 1, a link is assumed between allele 2 and haplo-
arrier haplotypes. Each dot represents a SNP allele, shaded with the
to (red, disease haplotype; blue, unaffected haplotype). Each line
used to generate the haplotype. Viewpoint SNPs are indicated in
oids (C) GenBank: NM_000492.3; c.[1652_1654del];[482G>A] and
e IB3-1 cell line (E) GenBank: NM_000492.3; c.[1652_1654del];
in the 9 families included in this study, clustered per family. All
NPs. Blue bars indicate the reference allele (hg19) and green bars
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Figure 3. Determining the Fetal Fraction and Paternally Inherited Haplotype
(A) TLA haplotyping results for the parents of family 6.
(B) Sequence coverage obtained by targeted sequencing of cell-free DNA isolated from a pregnant mother (family 6). Across a 10 Mb
chromosomal interval, cell-free DNA sequence coverage almost exclusively localizes to a 710 kb region around CFTR (top), where it spe-
cifically accumulates at the target SNPs (in red, n ¼ 874) for which hybridization capture probes were designed (middle and bottom).
(C) Class 1 SNPs explained. Parents are homozygous for different variants, which enables estimating the fetal fraction in cell-free DNA.
(D) Boxplots of class 1 SNPs are shown for CFTR families 1 and 6. Bold line indicates the median, box indicates first to third quartile, and
whiskers extend from the first quartile minus 1.5 times the interquartile range to the third quartile plus 1.5 times the interquartile range.
(E) Class 2 SNPs explained. For these SNPs, the father is heterozygous and the mother is homozygous. Therefore, only one paternal
haplotype is detectable in cell-free DNA at each SNP position.
(F) Bar graphs show the class 2 SNPs identified in CFTR families 1 and 6 and the percentage of paternal alleles identified for each haplo-
type. Total read counts are shown inside the bars for each haplotype and the number of individual positions is noted above. The deduced
fetal fraction is shown for the inherited paternal haplotype.pregnant women, ranging from 6.1% to 32.8% (Figures 3D
and S9A).
Subsequently, the paternally inherited haplotype is
determined using SNPs where the father is heterozygous
and the mother is homozygous (class 2 SNPs) (Figure 3E).
At each of these positions, one paternal allele is discernible
and presence or absence of this variant over all class 2 SNPs
reveals which of the two paternal haplotypes was trans-
mitted (Figure 3F). In all nine instances, the paternally
inherited CFTR allele was readily discernible (Figure S9B).
Class 2 SNPs where the paternal haplotype is observed
are combined with the class 1 SNPs to more accurately
estimate the fetal fraction.
With the fetal fraction, paternally inherited haplotype,
and two maternally transmittable haplotypes known, we
could then deduce which allele was transmitted by the
mother. To identify maternally transmitted alleles, we
sub-classified all maternal heterozygous SNPs (class 3The AmericanSNPs) depending on whether the variant identical to
the variant inherited from the father was carried on
maternal haplotype 1 (denoted ‘‘type A’’) or on maternal
haplotype 2 (denoted ‘‘type B;’’ Figure 4A). For clarity: this
implies that the type A SNP alleles on maternal haplotype
2 and the type B SNP alleles on maternal haplotype 1 are
different from those inherited from the father (Figures 4A
and 4B). We then calculate for maternal haplotype 2 (the
‘‘disease’’ haplotypewhen themother is a carrier, see below)
the expected cfDNA ratios of its type A and type B SNPs, first
under the assumption that the mother transmits her
haplotype 1 and then under the assumption that she trans-
mits her haplotype 2 (Figure 4B). Under the first assumption
(maternal haplotype 1 is inherited), haplotype 2 will be un-
der-represented in its type A SNPs while its type B SNPs will
beneither enrichednordepleted.Under the secondassump-
tion (maternal haplotype 2 is inherited), type A SNPs origi-
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Figure 4. Determining the Maternally Inherited Haplotype
(A) Class 3 SNPs explained. After the paternal inherited haplotype is determined, the maternal heterozygous SNPs are sub-classified in
type A SNPs where thematernal haplotype 1 allele is equal to the paternal allele and type B SNPs where thematernal haplotype 2 allele is
equal to the paternal allele.
(B) Example calculations for the haplotype representations in type A and B SNPs for a family with a FF of 0.26 (as is the case with fam-
ily 1). In scenario 1, inheritance of maternal haplotype 1 is assumed, and in scenario 2, inheritance of maternal haplotype 2 is assumed.
(C) The expected distributions of A and B SNPs is made for inheritance of either maternal haplotype 1 or 2 (left of dashed line). The
observed distribution (right of dashed line) is then compared to these expected distributions. Plots are shown for CFTR family 1 and
6. The number of individual A and B SNPs are indicated in the lower right corner. Squares indicate the mean fraction of hap2 alleles,
whiskers indicate the 95% confidence interval, corrected for overdispersion.
(D) Statistical analysis of the observed haplotype 2 fractions in type A and B SNPs yields a probability for each of the four possible com-
binations of inherited haplotypes. Probabilities are shown for CFTR families 1 and 6.
(E) By combining the two expected inherited haplotypes, the fetal genotypewas predicted for all involved SNP positions. These predicted
genotypes were subsequently compared to the genotypes observed in the amniocentesis sample directly obtained from the fetus, to
determine the accuracy of the identified haplotypes, and the validity of the inheritance prediction. Data are shown for families 1 and 6.depleted, but cfDNAwill be enriched forhaplotype 2 in type
B SNPs (Figures 4B andS7). The expected level of over- or un-
derrepresentation differs per pregnancy and equals half the
previously estimated fetal fraction. We subsequently
compared the two expected distributions to the observed
fraction of haplotype 2 type A andB SNPs,while accounting
for overdispersion of allele counts (Figures 4C and S9C).
(Due to technical reasons this is common to next-genera-334 The American Journal of Human Genetics 101, 326–339, Septemtion sequencing data, but is often ignored; the observed
readcounts show a larger variance than would be expected
for the statistical models used for analysis. If not properly
accounted for, this overdispersion could result in over-esti-
mated confidence levels. See Material and Methods and
Technical Appendix.) Statistical testing of the observed
versus the expected distributions with the given fetal frac-
tion allowed us to determine the probability of eachber 7, 2017
Figure 5. MG-NIPD in a b-Thalassemia Risk Family
A family (HBB 7) with an identical mutation at chr11:5347806 (hg19) was admitted for a CVS at 11 weeks of pregnancy.
(A) TLA sequencing confirmed the presence of the heterozygous mutation (IVSII-1) at the downstream splice junction of HBB exon 2.
(B) Haplotypes were constructed in the 850 kb region surrounding HBB, using several viewpoints on heterozygous SNPs and a
viewpoint on the HBB gene.
(legend continued on next page)
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maternal haplotype being inherited (Figure 4D). The
confidence levels (adjusted for overdispersion) were used
in a posterior risk calculation for transmission of haplotype
2 (which may be hypothetically considered the disease
allele here, but know that these families are not at risk for
CF). Using our approach, in all cases we were able to predict
allele inheritance in the fetus with >99% confidence
(Table 1).
By combining the predicted parental haplotypes, we
constructed per fetus a predicted genotype across hundreds
of SNPs at the locus of interest. To validate the correctness
of our predictions and to assess the accuracy of the parental
haplotypes generated by TLA technology, we performed
targeted sequencing of the locus of interest using fetal
material obtained through amniocentesis. Targeted
sequencing of fetal material confirmed that, for all nine
couples, our method correctly predicted both the pater-
nally and maternally inherited CFTR alleles (Figures 4E
and S10). Further, the results also demonstrated that
99.08% of the 2,826 SNPs (including homozygous alleles
of class 1 and 2 SNPs) were correctly assigned by TLA to
one of the 18 inherited CFTR alleles (Table 1).
Next, to demonstrate that this method can readily be
adapted to other genomic loci in addition to CFTR, we
focused our MG-NIPD analysis on CYP21A2. Haplotyping
the CYP21A2 locus is more complex due to the nearby ho-
mologous pseudogene (CYP21A1P), which can induce
ambiguous mapping of sequence reads. To circumvent
this problem, we made sure that our TLA viewpoint
primers uniquely mapped to CYP21A2 sequences and
we sequenced longer (150 and 300 bp) reads. Altering
the primers and extending the read length enabled
unambiguous mapping to most CYP21A2 sequences
(Figure S11A). We applied CYP21A2MG-NIPD to two fam-
ilies (CYP 1 and CYP 3) and could predict, with >99.9%
confidence, the two inherited alleles for family 3 (Figures
S11B–S11F). The accuracy of prediction and of TLA-
generated haplotypes was again confirmed by the
sequencing of available amniotic cell DNA. Determining
haplotypes in CYP 1 was particularly challenging, as
the parents shared one haplotype (99% identical)
(Figure S11F). This scenario is analogous to many risk fam-
ilies with identical disease mutations (see for example
Figure S3H) and will therefore often be observed in clin-(C) Six class 1 SNPs were identified, with a median of 4.5% paternal
(D) In 220 SNPs, the paternalWT haplotype is visible, and representin
paternal affected allele would be visible if it was inherited, but only 0.
(E)Maternal heterozygous SNPs were classified type Awhere themate
B where the maternal affected allele was identical to the paternal inh
the dotted line, assuming either maternal allele is inherited. The ob
dotted line and clearly corresponds to the expected distribution if th
fraction of hap2 alleles, whiskers indicate the 95% confidence interv
(F) The probability of each of the four possible combinations of hapl
fetus carrying maternal affected allele is >99.9%.
(G) The inherited haplotypes were merged to a predicted fetal genotyp
the genotype observed after sequencing the CVS sample obtained dir
correct genotype prediction.
(H) Probability calculations for the other eight involved b-thalassem
336 The American Journal of Human Genetics 101, 326–339, Septemical practice. In these cases, class 1 SNPs (i.e., when par-
ents are homozygous for different variants) will be
(almost) absent, compromising assessment of the fetal
fraction. To circumvent this problem, we included an
unrelated locus (here, CFTR, though in practice one may
use a ‘‘neutral’’ locus not associated with disease) in our
analysis, which contributed class 1 and 2 SNPs for esti-
mating the fetal fraction (26%). In class 2 SNPs, for
which the father is heterozygous and the mother homo-
zygous, the shared haplotype will never be observed in
paternal-unique reads. However, the non-shared haplo-
type will be observable as usual. Despite the high fetal
fraction, the father’s unique haplotype was not observed
in cfDNA, making it statistically highly likely (see Material
and Methods) that he transmitted his shared allele. For
the mother’s shared allele this implied that there were
only type B SNPs (and no type A). Maternal haplotype
2 was significantly overrepresented in these type B
SNPs in cfDNA, which enabled us to predict with
>99.9% confidence that the fetus inherited the two
nearly identical CYP21A2 alleles, which was confirmed
by sequencing of fetal DNA obtained through amniocen-
tesis (Figure S11F).
Finally, we obtained material from 11 families known to
carry b-thalassemia (conferred by mutations in the HBB
gene) (Figures 5A and S12). We performed MG-NIPD as
described above, with the inclusion of a viewpoint near
the known disease mutations to firmly embed the muta-
tions in their haplotypes, and multiple additional view-
points across the HBB locus (Table S2). Two families
were excluded from analysis. In one case (HBB 3), the
parental white blood cells appeared degraded during inter-
national transport. In a second (HBB 10), we observed a
fetal fraction <1%, which was too low for accurate diag-
nosis. In the nine remaining cases, we were able to
robustly predict the inherited fetal disease status: four fe-
tuses were affected by b-thalassemia, four carried the
maternal disease allele, and one fetus was unaffected by
b-thalassemia (Figures 5A–5F and S13). All predictions
were confirmed by parallel invasive diagnostic tests (Fig-
ures 5G and S14), which also showed that 3,639 out of
the 3,699 (>98%) neutral and verifiable SNPs were
correctly phased by TLA technology to either the mutated
or the wild-type allele.alleles, indicating a 9% fetal fraction.
g 3.9% of sequence reads, indicating a FF of7.8%. In 67 SNPs, the
1% of reads are of the paternal allele, likely due to sequence errors.
rnalWTallele was identical to the paternal inherited allele and type
erited allele. The distribution of the affected allele is shown left of
served distributions of A and B SNPs is shown on the right of the
e maternal affected allele is inherited. Squares indicate the mean
al, corrected for overdispersion.
otypes is calculated, in this case the probability of a heterozygous
e, spanning 938 SNPs. This genotype corresponds very strongly to




In this work we have demonstrated that the combination
of targeted haplotyping of the two parents with targeted
sequencing of cell-free DNA extracted during pregnancy al-
lows for robust non-invasive prenatal diagnosis of mono-
genic diseases, without the need to include (or even
have) a first affected child for further genetic characteriza-
tion. We expect this will increasingly be recognized as
favorable now that pre-conception screening programs
for severe Mendelian disorders are being implemented in
our health care system, which inform young couples about
their carrier status even before the birth of a proband.
Recently, another study appeared which also demon-
strated that NIPD can be carried out without including a
proband for genetic characterization.21 Different from
our strategy that relies on targeted haplotyping of the locus
of interest though, their approach relies on 103 genomics-
based whole-genome haplotyping of both parents. This re-
quires purchasing the necessary equipment. It also seems
to make sequencing unnecessarily expensive and data
analysis and storage computationally more demanding.
In recognition thereof, the authors proposed that prior to
haplotype sequencing, a probe-based capture step can be
incorporated to specifically direct sequencing to the locus
of interest.21 The future will tell whether in terms of sensi-
tivity and accuracy, cost effectiveness, and readiness to
implement, either of the two approaches is to be preferred
over the other.
We believe an advantage of MG-NIPD is that it involves
targeted sequencing only of the gene of interest. This ex-
cludes the possibility of incidentally finding disease muta-
tions in other genes elsewhere in the genome, which
many clinicians will perceive as complicating and therefore
undesired during pregnancy. The targeted nature of MG-
NIPD also makes sequencing costs limited: haplotyping re-
quires only 3 million read pairs per parent, with cfDNA
sequencing requiring on average 9 million reads per family
(Table S4). The robustness of predictions made by our
method lies in the fact that it tests not only the likelihood
of a given allele being transmitted but also the likelihood
of the second allele not being transmitted, with each event
contributing similarly to the final risk calculation. Thus,
for a falsediagnosis tobemade, thenon-inheritedhaplotype
wouldhave tobe scored asbeingoverrepresented and the in-
herited haplotype as not being over-represented, which is
highly unlikely if the latter haplotype is contributed by
the fetus to the maternal blood. Therefore, it is far more
likely that MG-NIPD produces an inconclusive, rather
than a false-positive or false-negative, prediction. In fact,
in the family carryingHBBwith an extremely low (1%) fetal
cfDNA fraction, an inconclusive analysis was precisely the
result. The same may happen whenmeiotic recombination
has rearranged the locus of interest. The chance of this
happening inside the relatively small loci thatweare consid-
ering is low, yet one needs to be aware of this possibility. By
centering the locus of interest around the disease mutationThe American(rather than having it at the edge of the phased genomic in-
terval), recombination events will lead to inconclusive
rather than false predictions. In situations where MG-
NIPD results are inconclusive, the couple may still opt for
an invasive test. Further validation on larger numbers of
pregnancies is needed to determine whetherMG-NIPD pro-
vides the high degree of accuracy that is needed to eventu-
ally replace current invasive strategies forprenataldiagnosis.
For MG-NIPD, no specialized laboratory equipment is
required, making this a method that can be readily im-
plemented in any genetics laboratory. The principle shown
here is applicable to any risk locus where the disease-
causing sequence variant is known and where allele-
discerning SNPs are present within the risk locus. Our
current work focused on autosomal-recessive disorders,
but in principle the strategy should perform equally on
autosomal-dominant disorders, also if the mother were
the carrier. Embedding triplet repeat expansions in their
haplotypes by TLA is less trivial: extending this approach
to disorders caused by such expansions would therefore
require further optimization. We anticipate that MG-
NIPD will be an attractive means to give couples additional
comfort early during pregnancy that the embryo selected
by pre-implantation genetic diagnostics (PGD) is indeed
not affected, which for technical reasons cannot fully be
excluded by PGD.37,38 Finally, modified versions of the
MG-NIPDmethod presented heremay offer a non-invasive
and easy way to confirm parenthood, for example
following in vitro fertilization. Thus, in many cases in
future prenatal diagnostics, a simple blood test could give
desired comfort during pregnancy and replace more
burdensome and risky invasive tests such as CVS and
amniocentesis. The scripts used in this publication are
publicly available through github (see Web Resources).Accession Numbers
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